European Medicines Agency Validates Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Review

RegulatoryLorecivivintPositive

AI Analysis

The European Medicines Agency has validated Biosplice's application for lorecivivint in knee osteoarthritis and initiated its review process.

Application validated and review begun by EMA

Importance:7/10

Sentiment:

0.60

EMAregulatoryosteoarthritislorecivivintapplication validation

Read the original article

Published by GlobeNewswire Clinical Studies on October 2, 2026 10:00 AM